Boris Rodenko

(Acerta Pharma B.V.)

Associate Director Biology and Translational, Acerta Pharma.

I am Head of Biology and Translational Sciences at Acerta Pharma, a member of the AstraZeneca group.  Our company has developed Calquence, a covalent BTK inhibitor approved for the treatment of chronic lymphatic leukaemia and mantle cell lymphoma.  The Translational team processes patient samples for pharmacodynamic analysis of experimental medicines.  The early stage drug discovery team is working on validated drug target projects, and also tries to validate novel targets in Haematological Oncology.  To do this we need to understand the biology of B-cell tumours and the interplay with their microenvironment.  For this reason, we are keen to contribute to the Target 2 B! Consortium.

Recent publications involving Acerta Pharma include:

  1. Discovery of quinoline-based irreversible BTK inhibitors. De Bruin G, et al. Bioorg Med Chem Lett. 2020;30(14):127261. doi: 10.1016/j.bmcl.2020.127261.
  2. Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib. Awan FT, et al. Blood Adv. 2019;3(9):1553-1562. doi: 10.1182/bloodadvances.2018030007.
  3. Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile. Barf T, et al. J Pharmacol Exp Ther. 2017;363(2):240-252. doi: 10.1124/jpet.117.242909.
  4. Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia. Byrd JC, et al. N Engl J Med. 2016;374(4):323-332. doi: 10.1056/NEJMoa1509981.

Member of work packages 2, 5 and 7.

Back To Top